Mysildecard (Sildenafil)

• Mysildecard, a PDE5 inhibitor, acts on the nitric‑oxide‑cGMP pathway to improve vascular smooth‑muscle relaxation in specific conditions.
• Erectile dysfunction: enhances ability to achieve and maintain an erection sufficient for sexual activity.
• Pulmonary arterial hypertension: lowers pulmonary vascular resistance and improves exercise capacity.
• Diabetes‑related sexual dysfunction: improves erectile response in men with diabetes.

• Sildenafil selectively inhibits phosphodiesterase type 5, preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to smooth‑muscle relaxation in the corpus cavernosum and pulmonary vasculature, facilitating increased blood flow and the therapeutic effects observed in erectile dysfunction and pulmonary arterial hypertension.

Sildenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache
• Facial flushing
• Dyspepsia or indigestion
• Nasal congestion
• Visual disturbances (e.g., blurred vision, color tinge)
• Myalgia or back pain

Serious or Rare Side Effects

• Priapism (prolonged erection lasting >4 hours)
• Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy)
• Sudden hearing loss or tinnitus
• Myocardial infarction or severe cardiac events
• Stroke or transient ischemic attack
• Severe hypotension, especially with nitrate use

Before prescribing Mysildecard, clinicians should evaluate patient‑specific risk factors and contraindications.

• Cardiovascular assessment: ensure the patient can safely engage in sexual activity.
• Nitrate use: avoid co‑administration due to risk of profound hypotension.
• Retinitis pigmentosa: use with caution as visual side effects may be exacerbated.
• Concomitant alpha‑blockers: monitor blood pressure closely.
• Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Sildenafil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin, isosorbide dinitrate): risk of severe hypotension.
• Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sildenafil exposure.

Moderate Interactions (Monitor Closely)

• Alpha‑blockers (e.g., tamsulosin): may cause additive blood‑pressure lowering.
• Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): monitor for excessive hypotension.